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ABSTRACT
Purpose: Helicobacter pylori infection can lead to gastric
cancer, and cyclooxygenase-2 (COX-2) is overexpressed in
the stomach during H. pylori infection. Therefore, we inves-
tigated whether nonsteroidal anti-inflammatory drugs
might protect against this form of cancer. Specifically, we
examined the chemopreventive effect of the COX-2 inhibitor
nimesulide on H. pylori-associated gastric carcinogenesis in
mice.
Experimental Design: C57BL/6 mice were treated with
the carcinogen N-methyl-N-nitrosourea (MNU) and/or H.
pylori. To determine the effect of COX-2 inhibition, nime-
sulide was mixed with feed pellets and administered for the
duration of the experiment. All of the mice were sacrificed
50 weeks after the start of the experiment. Histopathology,
immunohistochemistry, and Western blotting for COX-2,
Bax and Bcl-2 were performed in stomach tissues. In vitro
experiments with the human gastric cancer cell line AGS
were also performed to identify mechanisms underlying can-
cer chemoprevention by nimesulide.
Results: Gastric tumors developed in 68.8% of mice
that were given both MNU and H. pylori, whereas less than
10% developed gastric tumors when given either MNU or H.
pylori alone. These findings indicate that H. pylori promotes
carcinogen-induced gastric tumorigenesis. In mice treated
with both MNU and H. pylori, nimesulide administration
substantially reduced H. pylori-associated gastric tumori-
genesis, whereas substantial inductions of apoptosis were
observed. In vitro studies demonstrated that nimesulide and
H. pylori when combined acted synergistically to induce
more apoptosis than either alone.
Conclusions: Our data show that nimesulide prevents
H. pylori-associated gastric carcinogenesis, and suggest that
COX-2 may be a target for chemoprevention of gastric
cancer.
INTRODUCTION
Helicobacter pylori causes chronic active gastritis and pep-
tic ulcer disease, and is linked with gastric adenocarcinomas,
including gastric mucosa-associated lymphoid tissue lymphoma
(1). On the basis of epidemiologic data, WHO/IARC classified
H. pylori as a group 1 carcinogen (2). Generally, gastric ade-
nocarcinoma develops through a multistep process from normal
gastric mucosa to chronic active gastritis, to gastric atrophy and
intestinal metaplasia, and finally to dysplasia and neoplasia (3),
and it has been postulated that H. pylori plays a causative role
in the early phases of this malignant progression (4, 5). How-
ever, debate still exists as to whether H. pylori is really a
carcinogen or a cancer promoter, and whether eradication of
H. pylori is beneficial to people free of gastric tumors (6–9).
A possible explanation for the link between H. pylori
infection and gastric carcinogenesis is that H. pylori infection
raised cyclooxygenase-2 (COX-2) mRNA/protein levels, and
stimulated release of prostaglandin E2 in H. pylori-associated
premalignant and malignant gastric lesions (10–16). There is
strong evidence that COX-2 is causally involved in gastrointes-
tinal cancer (17–22). In addition, growth of colon polyps was
retarded or blocked by either administration of nonsteroidal
anti-inflammatory drugs (NSAIDs; refs. 23–25) or targeted de-
letion of the COX-2 gene (26). Because induction of COX-2
expression has been shown to play an important role in neo-
plastic transformation in the large intestine, it is our hypothesis
that COX-2 is involved in H. pylori-associated gastric cancer
development, and that NSAID administration can prevent or
retard this process.
It has been shown that H. pylori increased release of
prostaglandin E2 and COX-2, which were overexpressed in most
metaplastic and adenomatous tissues, as well as in gastric ade-
nocarcinoma (27). Despite these observations, it remains un-
known as to whether COX-2 may be a target for chemopreven-
tion of H. pylori-associated gastric carcinogenesis. In the
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present study, we used an H. pylori-associated gastric cancer
mouse model (28, 29) to investigate the preventive effects of the
selective COX-2 inhibitor nimesulide, and we studied the mech-
anisms underlying nimesulide-induced chemoprevention with
AGS human gastric cancer cell line.
MATERIALS AND METHODS
Mice. Male C57BL/6 mice were obtained from the Jack-
son Laboratory (Bar Harbor, ME) at 5 weeks of age. The mice
were maintained in an accredited Korea FDA animal facility in
accordance with the AAALAC International Animal Care pol-
icies (Accredited Unit-Korea Food and Drug Administration:
Unit Number-000996). All of the mice were given a standard
pellet chow diet (CRF-1, Oriental Yeast Co. Ltd., Tokyo, Japan)
ad libitum and were maintained in specific pathogen-free con-
ditions.
Chemicals and Bacteria. N-methyl-N-nitrosourea
(MNU; Sigma Chemical Co., St. Louis, MO) solutions were
freshly prepared twice a week by dissolving 200 ppm MNU in
distilled water. When indicated, mice were given the 200-ppm
MNU solution ad libitum in light-shielded bottles in place of
drinking water. Mouse-adapted H. pylori (SS1) were inoculated
on Brucella agar plates (Becton Dickinson, Cockeysville, MD)
containing 10% heat-inactivated fetal bovine serum and Skirrow
medium (Difco, Detroit, MI). They were kept at 37°C under
microaerobic conditions with GasPak jars (Difco) and Campy-
Paks (Becton Dickinson). After 24 hours of fasting, a 0.1-mL
suspension of H. pylori containing 1  109 colony-forming
units (CFU)/mL was administered by intragastric intubation.
Study Design. The experimental design is illustrated in
Fig. 1. Mice were randomized into five groups. Animals of
groups 2, 3, and 5 were given MNU. One week after completion
of MNU administration, mice in groups 3 and 5 were inoculated
with H. pylori three times every other day. Mice in groups 1 and
4 were inoculated with H. pylori three times every other day (no
MNU treatment). Animals of groups 4 and 5 were then given a
CRF-1 diet (Oriental Yeast Co. Ltd.) containing 200 ppm nime-
sulide (Choongwae Pharmaceutical Research Institute, Suwon,
Korea). Animals of groups 1, 2, and 3 were maintained on basal
CRF-1 diets throughout the experiment. Mice were sacrificed 38
weeks after infection, making a total of 50 weeks of treatment.
Histopathologic Examination. Immediately after sacri-
fice, mouse stomachs were opened along the greater curvature.
The number, as well as the long diameter, of tumors in the
stomach was measured. A record was kept of the size and
number of tumors counted, with a diagnosis made after the final
histopathologic examination. One half of the excised stomachs,
including neoplastic nodules, were fixed in neutral-buffered
10% formalin and were cut into approximately six strips, which
were processed by standard methods, embedded in paraffin,
sectioned at 4 m, and stained with hematoxylin and eosin
(H&E). The remaining portions were quickly frozen in liquid
nitrogen and stored at 70°C until analysis. Histologic classi-
fication was based on histopathologic and cytologic criteria
proposed by Leininger and Jokinen (30). After histopathologic
classification was done, tumor incidence and multiplicity was
calculated.
Identification of H. pylori in Gastric Mucosa. To con-
firm H. pylori infection, we transferred samples (3-mm2) of
stomach mucosa from the greater curvature containing both
fundic and pyloric glands to 1.0 mL of sterile 0.1 mol/L PBS;
these were homogenized and plated on selective trypticase soy
agar/5% sheep blood plates containing vancomycin (20 mg/
mL), nalidixic acid (10 mg/mL), bacitracin (30 mg/mL) and
amphotericin B (2 mg/mL) from Sigma Chemical Co., and
grown for 3 to 5 days. Colonies were identified by characteristic
Gram’s stain morphology, and by urease, catalase, and oxidase
activity. Another 3-mm2 sample from the antrum was placed
into the gel of a rapid urease test kit (CLO test, Ballard Medical
Products, Draper, VT) and was left for 6 hours at room temper-
ature to test for urease activity. The presence of H. pylori in the
gastric pit was further confirmed by Warthin–Starry staining.
Immunohistochemistry for COX-2. Immunohisto-
chemical identification of COX-2 expression was performed on
replicate sections of stomach tissues. The sections were
mounted on silanized slides (Dako, Glostrup, Denmark) and
were dewaxed and rehydrated; endogenous peroxidase activity
was quenched with hydrogen peroxide. After washing in dou-
Fig. 1 The study design. Ani-
mals were randomized into five
groups according to treatment:
group 1, H. pylori alone (Hp
alone); group 2, MNU alone;
group 3, five weeks’ MNU ad-
ministration followed by H. py-
lori infection; group 4, H. py-
lori infection followed by
continuous nimesulide via diet
[NIM (po)]; and group 5, five
weeks’ MNU administration
followed by H. pylori infection
and nimesulide treatment [NIM
(po)]. The mice were sacrificed
38 weeks after H. pylori in-
fection.
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ble-distilled water, sections were subjected to microwave anti-
gen retrieval in 0.01 mol/L citric acid. The slides were incubated
at 4°C overnight with rabbit anti-COX-2 polyclonal antibody
(1:2,000; Cayman Chemical, Ann Arbor, MI). Immunoreaction
complexes were detected with the avidin-biotin affinity system
(Santa Cruz Biotechnology, Santa Cruz, CA) and were visual-
ized with 3,3-diaminobenzidine tetrahydrochloride (Zymed
Laboratories Inc., San Francisco, CA) as the chromogen. The
sections were counterstained with Mayer’s hematoxylin and
examined under a light microscope.
Western Blotting. The frozen stomach tissues were ho-
mogenized in radioimmunoprecipitation assay (RIPA) buffer
[10 mmol/L Tris (pH 7.6), 1 mmol/L EDTA (pH 8.0), 100
mmol/L NaCl, 1 g/mL aprotinin, and 100 g/mL phenylmeth-
ylsulfonyl fluoride (all from Sigma Chemical Co.)]. Protein
concentration was measured with the Bio-Rad Protein Assay kit
(Bio-Rad Laboratories, Hercules, CA). Extracted proteins (40
g/lane) were resolved by SDS-PAGE and were transferred to
polyvinylidene difluoride membranes. Membranes were incu-
bated overnight at 4°C with rabbit anti-COX-2 polyclonal anti-
body (Cayman Chemical), rabbit anti-Bax polyclonal antibody
(Santa Cruz Biotechnology), mouse anti-Bcl-2 monoclonal an-
tibody (Santa Cruz Biotechnology). The membranes were then
incubated for 45 minutes with secondary antibody (Santa Cruz
Biotechnology). After incubation with the secondary antibody,
blots were washed three times with PBS/0.1% Tween 20 and
developed with a commercial chemiluminescence detection kit
(Amersham Biosciences, Buckinghamshire, United Kingdom).
Expression levels of protein were quantified with a Bio-Rad
Imaging Densitometer system Model GS690 (Bio-Rad Labora-
tories) and the ratio of Bax to Bcl-2 was calculated.
The general procedure for Western immunoblot analyses of
cultured AGS cells with antibodies against caspase-3 (Santa
Cruz Biotechnology), (poly)ADP-ribose polymerase (PARP;
Zymed Laboratories Inc.) were similar to the procedures de-
scribed above. Cultured cells were washed twice with cold PBS
on ice and harvested by scraping with a rubber scraper. Cells
were sedimented by centrifugation at 4°C and resuspended in
cell extraction buffer (50 mM/L PIPES/NaOH, 2 mM/L EDTA,
0.1% CHAPS, 5 mM/L DTT, 20 g/mL leupeptin, 10 g/mL
pepstatin, 10 g/mL aprotinin, 1 M/L phenylmethylsulfo-
nyl fluoride).
Terminal Deoxynucleotidyl Transferase-Mediated Nick
End Labeling Assay. Apoptosis was visualized with terminal
deoxynucleotidyl transferase (TdT) FragEL DNA fragmentation
detection kit (Oncogene Research Products, Cambridge, MA).
The staining procedures were modified based on the manufac-
turer’s recommendations. Briefly, after routine deparaffiniza-
tion, rehydration, and washing in 1 PBS (pH 7.4), tissues were
digested with proteinase K (20 mg/mL in 1 PBS) for 20
minutes at room temperature and were washed. After incubation
in equilibration buffer for 10 minutes, sections were treated with
terminal deoxynucleotidyltransferase (TdT) enzyme at 37°C for
1 hour.
Determination of Apoptotic Index. All of the slides
were scored blindly three times without knowledge of the his-
tologic findings. To determine the apoptotic index (AI) in each
group, we first scanned Tdt-nick end labeling (TUNEL)-immu-
nostained sections under low power magnification (100) to
locate the apoptotic hot spots (areas with maximal TUNEL-
positive cells). The AI at 400 field was then scored by count-
ing the number of TUNEL-positive cells. At least five hot spots
in a section were selected to determine the average count. Data
were expressed as a mean percentage of total cell numbers.
Cell Culture and Cell Viability Assay. The human gas-
tric cancer cell line AGS was purchased from American Type
Culture Collection (ATCC strain, Manassas, VA) and was main-
tained in RPMI 1640 (Life Technologies, Inc., Gaithersburg,
MD) supplemented with 10% fetal calf serum (HyClone, Logan,
UT) in humidified environment at 37°C in 5% CO2. To deter-
mine the cell growth rate, we seeded AGS cells into 24-well
plate at 2  105 cells/mL in triplicate, and we pretreated them
with 5 mol/L nimesulide or celecoxib (Pfizer Pharma, New
York, NY) in 0.1% DMSO (Fisher Scientific, Pittsburgh, PA)
for 24 hours; we then used H. pylori inoculation (2  106
colony-forming units (CFU)/mL) for 24 hours. H. pylori filtrate
was prepared by homogenizing the bacteria in distilled water,
pelleting the bacteria by centrifugation, and then filtering
through a 0.2 m pore size filter (Gelman Sciences, Ann Arbor,
MI). Nimesulide and celecoxib were added when the cells had
70 to 80% confluency. Cell numbers and their viability were
determined by trypan blue exclusion assay.
Apoptotic Quantitation by Flow Cytometric Analysis.
Apoptotic cells were quantified by staining with FITC-conju-
gated Annexin V (Clontech, Palo Alto, CA). Cells (1  106)
were collected at 72 hours for flow cytometric measurement and
were stained with FITC-conjugated annexin V and propidium
iodide as recommended by the manufacturer, and were then
analyzed by flow cytometry with a FACScan (Becton Dickinson
Facsort flow cytometer) with an argon laser set to excite at 488
nm. Propidium iodide (40 g/100 L PBS) was added to 1 
106 cells suspended in 800 L of PBS, together with 100 L of
RNase A (1 g/mL), and was incubated at 37°C for 30 minutes
before flow cytometry analysis of 2  104 cells. Red fluores-
cence of propidium-bound DNA was measured with a 630
nm-long bandpass filter.
Statistical Analyses. The data were analyzed with the
JMP software package (version 4.0; SAS Institute, Cary, NC) on
an IBM computer. Stomach tumor incidence data were analyzed
with a 2 test. Other data were compared with the Dunnett t test
after ANOVA analysis. For all comparisons, P values less than
5% (P  0.05) were considered to be statistically significant.
RESULTS
Bacterial Colonization. At week 50, stomachs were re-
moved, and all of the mice except those in group 2 (MNU alone)
showed positive H. pylori colonization as determined by direct
bacterial culture and rapid urease tests. The mean (SEM) number
of CFU recovered from mice inoculated orally with H. pylori
SS1 was 1.41  (0.35)  105/mg gastric tissue. Warthin–Starry
staining showed numerous spiral bacteria in mucosal epithelium
along the length of the gastric pits in both the antrum and the
body of all of the animals inoculated with H. pylori.
H. Pylori Infection Promoted Carcinogen-Induced Gas-
tric Tumorigenesis. Mice were randomized into five groups
according to treatment: group 1, H. pylori alone; group 2, MNU
alone; group 3, five weeks’ MNU administration followed by H.
8107Clinical Cancer Research
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pylori infection; group 4, H. pylori infection followed by con-
tinuous nimesulide via diet; and group 5, five weeks’ MNU
administration followed by H. pylori infection and nimesulide
treatment (see Fig. 1). The mice were sacrificed 38 weeks after
H. pylori infection. The mean body weight of each group was
similar throughout all of the experiments. The incidence of
tumors at sacrifice was 0% (0/13) in group 1, 10% (1/10) in
group 2, and 68.8% (11/16) in group 3. Group 3 showed a
significantly higher incidence of gastric tumor compared with
groups 1 and 2 (P  0.0001 for both comparisons), signifying
that the mice were somewhat resistant to carcinogen-stimulated
gastric tumorigenesis, and that H. pylori infection promoted,
rather than initiated, gastric tumorigenesis. In addition to in-
creased tumor incidence, tumor multiplicity was higher in group
3 than in group 2 (2.62  0.36 versus 0.10  0.10: P  0.01;
Table 1). Tumors were mostly formed in the pyloric mucosa
adjacent to the fundic region. Macroscopically, the majority of
tumor masses were polypoid, like type I stomach cancers in
humans (Fig. 2A), and some were sessile.
Nimesulide Significantly Suppressed H. pylori-Associ-
ated Gastric Carcinogenesis. The incidence of overall stom-
ach tumors was lower in group 5 (MNU3H. pylori 	 nimesu-
lide) compared with group 3 [MNU3H. pylori; 27.8% (5/18)
versus 68.8% (11/16); P  0.01]. In addition, the multiplicity of
gastric tumors in group 5 was lower than that in group 3 (0.44
0.12 versus 2.62  0.36; P  0.05; Table 1). Although there
was no significant difference in the incidence of gastric ade-
noma between groups 3 and 5 (Table 2), the incidence of gastric
adenocarcinoma was markedly reduced in group 5 compared
with group 3 [5.6% (1/18) versus 43.8% (7/16); P  0.01; Table
2). These data indicate nimesulide inhibited either the develop-
ment of H. pylori-associated gastric tumorigenesis or the proc-
ess of gastric carcinogenesis.
Histologic Features of H. pylori-Associated Gastric
Cancer. In group 1, the fundic and pyloric mucosa revealed
chronic gastritis characterized by moderate-to-severe infiltration of
lymphocytes, plasma cells, and a few neutrophils with foveolar
hyperplasia (Fig. 3A); and in group 4, mild infiltration of inflam-
matory cells as well as epithelial hyperplasia was observed, but less
than in group 1. The adenoma frequently noted in groups 2, 3, and
5 revealed irregular small compact glandular growths composed of
pencil-like and hyperchromatic nuclei, and a few mitotic figures.
Occasionally, superficial erosions covered with pinkish amorphous
hemorrhagic debris were found on the surface of adenomas in
group 3. However, there was no definite stromal invasion (Fig. 3B).
Gastric adenocarcinoma, frequently found in group 3, showed an
irregular glandular proliferation with solid pattern and angular
structure indicative of early stromal invasion. The adenocarcinoma
showed an atypical irregular glandular hyperplasia with cribriform
appearance, which was composed of hyperchromatic atypical tu-
mor cells (Fig. 2C and Fig. 3C). Small irregular atypical glands
were observed infiltrating into the muscularis mucosa and submu-
cosa (Fig. 3D).
Attenuated Expression of Gastric COX-2 in Nimesu-
lide-Treated Mice. Immunohistochemistry revealed that
COX-2 protein was expressed primarily in stromal cells of the
laminar propria in gastric adenocarcinoma, and was character-
ized by a strong, intense cytoplasmic expression pattern (Fig.
4Aa and Ac). COX-2 was very strongly localized, not only in the
area of gastritis but also in the stromal cells adjacent to erosion,
displaying a spotty cytoplasmic staining pattern, and was limited
to a small number of epithelial cells in gastric adenomas (Fig.
Fig. 2 Macroscopic (A) and microscopic (B and C) appearance of gastric cancer. A, multiple polypoid tumors developed in the stomach after MNU
and H. pylori infection. B, the polypoid mass shows an intramucosal adenocarcinoma with foveolar epithelial hyperplasia in the antrum and pylorus
(100). C, the adenocarcinoma shows an atypical irregular glandular hyperplasia with cribriform appearance, which is composed of hyperchromatic
atypical tumor cells (200).
Table 1 Incidence and multiplicity of glandular
stomach tumors in mice
Group
Effective no.
of mice*
No. of tumor-
bearing mice
(% incidence)
Tumor
multiplicity†
1. Hp alone 13 0 0
2. MNU alone 10 1 (10.0) 0.10  0.10
3. MNU3Hp 16 11 (68.8)‡ 2.62  0.36§
4. Hp 	 NIM 15 0 0
5. MNU3Hp 	 NIM 18 5 (27.8) 0.44  0.12¶
Abbreviation: Hp, H. pylori.
* Living mice with H. pylori at the time of sacrifice, except in
group 2 (MNU alone).
† Mean  SEM.
‡ P  0.0001 versus group 2.
§ P  0.01 versus group 2.
 P  0.01 versus group 3.
¶ P  0.05 versus group 3.
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4Ab). The overall intensity of COX-2 expression was lower in
nimesulide-treated groups (groups 4 and 5; Fig. 4B and Ad) than
in other groups (groups 1, 2, and 3; Fig. 4B and Ac). COX-2
levels in gastric mucosa homogenates were examined by West-
ern blotting, and we found that group 3 mice had the highest
level of homogenate COX-2, which was about 1.5-fold higher
than that in group 2 (Fig. 4B). The amount of COX-2 protein in
group 5 (MNU3H. pylori 	 nimesulide) homogenates was
significantly lower than that in group 3 (MNU3H. pylori). The
data indicate COX-2 expression in H. pylori-associated gastric
cancer was significantly inhibited by nimesulide treatment.
A Ratio of Bax to Bcl-2 Was Increased in Nimesulide-
Treated Mice. The mean expressions of proapoptotic Bax and
antiapoptotic Bcl-2 were measured in mixed homogenates of
stomach tissues according to each group. Compared with group
2 (MNU alone), the mean expression of Bax in group 1 (H.
pylori alone) was markedly increased, and the mean expression
of Bcl-2 was rather decreased after H. pylori infection than in
group 2, suggesting that significant apoptotic-prone tendency
was induced after H. pylori infection. Interestingly, the expres-
sion of Bcl-2 in group 3 (MNU3H. pylori) was significantly
increased, but the expression of Bax was attenuated, resulting in
significant decreased in the mean ratio of Bax/Bcl-2 intensity.
Significant increases in the expression of Bax were observed in
groups treated with nimesulide (groups 4 and 5), signifying that
the apoptotic actions of nimesulide might be the reason why
carcinogenesis was ameliorated in animal groups treated with
nimesulide (Fig. 4C).
Both COX-2 Inhibitor and H. pylori Acted Synergisti-
cally to Increase Apoptosis: A Possible Chemopreventive
Mechanism of Nimesulide. On the basis of these observa-
tions of Fig. 4C, we measured the degree of apoptosis in
Fig. 3 Histopathology. A, fundic mucosa in group 1 revealed a patchy infiltration of chronic inflammatory cells with foveolar epithelial hyperplasia.
B, adenoma in group 5 animals showed an irregular small glandular proliferation composed of high cellular, pencil-like, and hyperchromatic nuclei.
C, adenocarcinoma in group 3 animals revealed a marked glandular proliferation with nuclear atypia and early stromal invasion. D, invasive
adenocarcinoma in group 3 animals revealed small irregular carcinomatous glands infiltrating the muscularis mucosa and submucosa, accompanied
by desmoplasia. 100; portion enlarged (on the left): 200.
Table 2 Incidence of glandular stomach tumors: histopathologic findings
Group
Effective
no. of mice
No. of tumor-
bearing mice
Gastric
adenoma (%)
Gastric
adenocarcinoma (%)
1. Hp alone 13 0 0 0
2. MNU alone 10 1 1 (10) 0
3. MNU3Hp 16 11 4 (25.0) 7 (43.8)
4. Hp 	 NIM 15 0 0 0
5. MNU3Hp 	 NIM 18 5 4 (22.2) 1 (5.6)*
Abbreviation: Hp, H. pylori.
* P  0.01 versus group 3.
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stomach tissues of each animal according to group with the
TUNEL method. As shown in Fig. 5A, H. pylori infection
increased the TUNEL staining of positive cells, but the apop-
totic activities were markedly decreased in the portion of gastric
adenoma. However, nimesulide administration increased
TUNEL staining positive cells irrespective of gastric patholo-
gies. Even in tumor tissues, significant apoptotic positive cells
were noted in group treated with nimesulide, suggesting the
active apoptotic activities might be the fundamental mecha-
nisms of nimesulide on attenuated H. pylori-associated carcino-
genesis. The mean changes of apoptotic index were shown in
Fig. 5B.
When AGS cells were treated with 5 mol/L nimesulide
(preferred COX-2 inhibitor) or 5 mol/L celecoxib (selective
COX-2 inhibitor) or H. pylori (2  106 CFU), a significant
decrease in cell survivals was observed with all three treatments,
which was measured with cell counts (Fig. 6A). Significant
attenuation in cell survivals was noted in cells treated with either
celecoxib or nimesulide alone. These changes were more evi-
dent in cells cotreated with a COX-2 inhibitor and H. pylori,
suggesting that cell death processes were more activated than
with either COX-2 inhibitor or H. pylori alone. All of these
findings that the combination of COX-2 inhibitor and H. pylori
provoked and augmented apoptosis were more evidenced with
Western blot of caspase-3 and PARP (Fig. 6B) and with flow
cytometry analyses (Fig. 6C). Active caspase-3, cleavage of
PARP, and increased fractions of positive annexin V—observed
after COX-2 inhibitor treatment—were more apparently in-
creased after the cotreatment of COX-2 inhibitor and H. pylori.
These in vitro experiments explain the similar mechanistic basis
of the cancer prevention of nimesulide treatment in H. pylori-
associated gastric tumorigenesis as observed in in vivo animal
experiment. Attenuated development of gastric tumor in previ-
ous animal experiments could be achieved because both the
COX-2 inhibitor and H. pylori acted synergistically to increase
apoptosis, a possible chemopreventive mechanism of nimesu-
lide.
DISCUSSION
The present study shows that H. pylori-associated gastric
tumorigenesis and carcinogenesis was effectively suppressed by
Fig. 4 Expression of COX-2, Bax, and Bcl-2. A, immunohistochemical staining for COX-2. In Aa, COX-2 expression was mainly confined to stromal
cells composed of macrophages, lymphocytes, and interstitium in gastric adenocarcinoma. Ab, gastric adenoma epithelial cells expressing COX-2. In
Ac and Ad, COX-2 expression was attenuated in nimesulide (NIM)-treated animals (Ad) compared with non-NIM-treated animals (Ac); 200. B,
COX-2 protein expression levels in the experimental groups. Western blot analysis of COX-2 protein expression in stomach tissues (Hp, H. pylori;
kDa, Mr in thousands). C, Bax and Bcl-2 expression levels in the experimental group. Bax and Bcl-2 expressions in stomach tissues were demonstrated
according to group, and the ratio (Bax/Bcl2) of the expression was depicted. kDa, Mr in thousands.
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the selective COX-2 inhibitor nimesulide. COX-2 protein was
highly expressed in stromal cells of H. pylori-associated tumor
tissues, which expression levels substantially decreased after
nimesulide administration. In addition, significant inductions of
apoptosis were observed. The results of in vitro experiments
suggested that nimesulide and H. pylori synergistically operated
to induce more apoptosis in AGS cells. These findings indicate
that the inhibition of COX-2 activity might be a novel target for
the treatment and prevention of H. pylori-associated gastric
cancers, which are similar to colon cancers.
Cancer is the result of a multistep molecular and cellular
process. Chemoprevention might be a better way to manage
cancer rather than the current chemotherapy with cytotoxic
agents in every aspect of efficacy, compliance, and feasibility.
For this purpose, noncytotoxic nutrients or pharmacological
compounds that might protect against the development and
progression of mutant clones into malignant cells have been
used in experimental and clinical studies (31). Nimesulide, a
preferred selective inhibitor of COX-2 belonging to the sulfon-
amide class, has been used clinically as an anti-inflammatory
drug with less ulcerogenic effects in the gastrointestinal tract
than classical NSAIDs. It is regarded as a good candidate agent
in chemopreventive trials against colon and breast cancers (32).
A large body of recent epidemiologic data suggests regular
NSAID use can reduce both the incidence of, and mortality
from, colorectal cancer and other solid tumors such as breast
cancer (19, 23–25, 33).
It has been postulated that the protective effects of NSAIDs
are mediated through the inhibition of cyclooxygenase enzymes,
COX-1 and COX-2 (19, 22). COX-2 leads to increased synthe-
sis of prostaglandins in both inflammatory and malignant tis-
sues, and may support the development and progression of
human malignancy. Recently, a more direct causal link between
COX-2 expression and malignancy was shown in studies of
COX-2-overexpressing transgenic mice (34), which displayed
mammary gland hyperplasia and transformation in breast tissue
overexpressing COX-2. Similarly, COX-2 “knockout” mice
showed reduced intestinal polyp development (26), again sup-
porting a causative role of COX-2 in tumorigenesis. Studies of
human colorectal tumors revealed that COX-2 is overexpressed
in more than 80% of carcinomas and in at least 50% of prema-
lignant adenomas (22). Furthermore, COX-2 inhibitors effec-
tively reduced colorectal tumors induced by azoxymethane
treatment in rats, and spontaneous colorectal tumors in Apc/
Min mice (24, 35). On the basis of preclinical profiles that
COX-2 was highly expressed in polyp tissues obtained from
patients with familial adenomatous polyposis (FAP), celecoxib
entered a phase III randomized trial in 77 FAP patients. After 6
months of 400-mg intake twice daily, celecoxib caused a 28%
reduction in polyp burden in the rectum (25).
Several studies have shown enhanced COX-2 expression in
gastric cancer tissues (18, 27). Overexpression of COX-2 was a
property shared by both intestinal and diffuse gastric carcino-
mas. It seems that COX-2 might play an important role during
the early stage of gastric carcinogenesis (16, 27). H. pylori
infection is a major risk factor for gastric carcinoma. H. pylori
up-regulated COX-2 mRNA expression and stimulated release
of prostaglandin E2 in a gastric cancer cell line (10), as well as
in the gastric mucosa of animal models and in humans (12, 14).
Therefore, high levels of H. pylori infection might up-regulate
COX-2 expression, which, in turn, could lead to the develop-
ment of gastric carcinogenesis (27). Experimentally, Xiao et al.
(14) demonstrated that COX-2 was directly involved in hyper-
plastic changes in mice infected with H. pylori. Consistent with
the data from the above-mentioned studies, the present findings
strongly support the contention that pharmacological inhibition
of COX-2 overexpression may be useful against H. pylori-
associated gastric cancer development and progression.
H. pylori and NSAIDs are known to be risk factors in the
pathogenesis of gastric ulcers through apparently different
mechanisms, reciprocally or independently. H. pylori infection
may induce strong mucosal inflammation, stimulate cytokine
release, and provoke apoptosis. H. pylori had been known to be
responsible for significant apoptosis, by which gastric ulcer-
ations or gastric atrophy (significant apoptotic cell death of
gastric stem cells or parietal cells) can be developed. For this,
several cytotoxins of CagA or VacA, ammonia generated from
urease actions, chemokines, or cytokines like interleukin (IL)-8,
interferon-
, IL-12, tumor necrosis factor , oxidative stress,
and HNP (helicobacter neutrophil-activating peptide), and so
forth, had been known to be responsible for apoptosis after
H. pylori infection. In contrast, NSAIDs may inhibit mucosal
prostaglandin synthesis, leading to a weakening in the gastric
mucosal barrier, and impaired resistance to acid injury. There-
fore, one might expect increased incidence of gastric mucosa
damage in the presence of these two risk factors (36). However,
Fig. 5 TUNEL staining and apoptotic index. A, TUNEL staining pos-
itive cells were increased after H. pylori infection (Group 1), but the
apoptotic activities were markedly decreased in gastric adenoma tissue
(Group 3). However, nimesulide administration provoked increased
apoptotic activities either in nontumor tissue of Group 4 or in tumor
tissue of Group 5. B, mean index (MSD) of apoptosis is shown,
resulting in statistically increased apoptotic index in group treated with
nimesulide irrespective of the presence of gastric tumor.
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we found no evidence of any gastric mucosal damages in mice
stomachs (group 4) assessed either by gross inspection or his-
tologic evaluation, although the combination of COX-2 inhibi-
tor and H. pylori did augment apoptosis in in vitro experiments
(Fig. 6). The presence of H. pylori and coexisting gastritis has
been shown to increase (37), have no effect (38), and even
decrease (39), the risk of ulcer bleeding among patients
ingesting aspirin or NSAIDs. In the present study, we found
that despite long-term exposure to these two risk factors in
groups 4 and 5, there was no increase in gastric inflammation
or mucosal destruction compared with groups 1 and 2, which
were exposed to a single risk factor. As for the explanations,
we inferred that gastric defense mechanisms operated well in
the groups exposed to both H. pylori and COX-2 inhibitor,
and nimesulide administered to the H. pylori-infected mice
must have blocked the effects of COX-2 on cellular pro-
liferation, release of inflammatory mediators, and cell adhe-
sion to matrix, which cause increased gastric inflammation
(40). Moreover, H. pylori-alone provoked cellular apoptosis,
whereas NSAID-alone also contributed to apoptosis either by
COX-2 inhibition or by direct activation of other cellular
targets such as peroxisome proliferator-activated receptor 

observed in our present experiment (data not shown; ref. 41).
In vitro experiments in this study showed the synergistic
effects of cotreatment with COX-2 inhibitor and H. pylori on
apoptosis and inhibition of proliferation. Recently, Kern et
al. (42) suggested that hepatocarcinogenesis could be pre-
vented by COX-2 inhibitors, based on the induction of apo-
ptosis and the inhibition of proliferation; and data from
Reddy et al. (19) strengthened the argument that selective
COX-2 inhibitors possess chemopreventive activity against
colon carcinogenesis.
In conclusion, we found that gastric tumorigenesis was
significantly attenuated by long-term administration of the
COX-2 inhibitor, nimesulide, in an H. pylori-associated gastric
cancer mouse model, and we propose that selective COX-2
inhibitors may be clinically useful in protecting against gastric
cancer development.
Fig. 6 In vitro experiments with AGS cells. A, cell survivals after each treatment analyzed by cell counts. Statistically significant decreases in cell
survival were observed in AGS cells treated with both COX-2 inhibitor and H. pylori than were seen in cells treated with COX-2 inhibitor alone (P 
0.01) or H. pylori alone (P  0.05). B, Western blot analysis of active form of caspase-3 and PARP. Significant decrease in the expression of active
caspase-3 and cleavage of PARP were observed after both H. pylori and COX-2 inhibitor, signifying the occurrence of apoptotic cells death in cells
treated with both COX-2 inhibitor and H. pylori infection. C stands for 5 mol/L celecoxib, N stands for 5 mol/L nimesulide. C, flow cytometry.
Fluorescence-activated cell sorter analysis for annexin V, and propidium iodide staining of AGS cells. The percentages give the proportion of cells
in the respective quadrant. Apoptosis was greatest in cells treated with both COX-2 inhibitor and H. pylori. 1, control cells (AGS cells, gastric cancer
cells); 2, cells treated with celecoxib (5 mol/L); 3, cells treated with nimesulide (5 mol/L); 4, cells infected with H. pylori (2  106 CFU); 5, cells
treated with celecoxib (5 mol/L) 	 H. pylori (2  106 CFU); 6, cells treated with nimesulide (5 mol/L) 	 H. pylori (2  106 CFU). (kDa, Mr
in thousands.)
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